C43 Profitability Analysis: Margins, Return on Capital, Free Cash Flow, and More - Cosmo Pharmaceuticals NV

Watchlist Manager

Watchlist

Price: 55.6 EUR -1.94%

Market Cap: €893.8m

	Cosmo Pharmaceuticals NV F:C43	IE
	Fluidra SA OTC:FLUIF	ES
	Samaraenergo PAO MOEX:SAGOP	RU
T	Tekcore Co Ltd TPEX:3339	TW
H	Hawesko Holding SE XMUN:HAW	DE
H	Horng Terng Automation Co Ltd TPEX:7751	TW
N	NovaGold Resources Inc XMUN:NGR	US
R	RMA Global Ltd ASX:RMY	AU

Profitability Summary

Cosmo Pharmaceuticals NV's profitability score is Hidden . We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.

Healthy Gross Margin

46%

Strong 3Y Average Gross Margin

64%

Declining Gross Margin

60% > 46%

Negative Operating Margin

-8%

Sustainable 3Y Average Operating Margin

19%

Declining Operating Margin

26% > -8%

Negative Net Margin

-6%

Sustainable 3Y Average Net Margin

15%

Declining Net Margin

10% > -6%

Negative Free Cash Flow Margin

-25%

Strong 3Y Average Free Cash Flow Margin

21%

Declining Free Cash Flow Margin

View All Checks

We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.